Home » Rapid Species Identification Using T2Direct Diagnostics™ with Stewardship Interventions
Rapid Species Identification Using T2Direct Diagnostics™ with Stewardship Interventions
Symposium presentation at MAD-ID 2019, The Antimicrobial Stewardship Meeting
This symposium shows how rapid diagnostic technology-based assays can be successfully incorporated into antimicrobial stewardship programs. The FDA-cleared T2Bacteria® and T2Candida® Panels provide clinicians with accurate species-specific diagnostic results in 3 to 5 hours directly from a 4 mL whole blood sample – without the wait for blood culture. The T2Bacteria and T2Candida Panels have demonstrated high specificity (>98%) in studies covering over 3,000 patients in more than 15 institutions. They can detect 90% of the most prevalent and common ESKAPE pathogens, enabling faster targeted therapy for patients with bloodstream infections. With exceptionally high negative predictive values (NPV) throughout a hospital – typically 98- 99% or more – the Panels have proven to provide stewardship teams the confidence to safely de-escalate empiric therapy and spare negative side effects for patients.
Debbie Goff, PharmD, FCCP, Associate Professor, The Ohio State University Wexner Medical Center
Ryan Shields, PharmD, MS, Associate Professor of Medicine, The University of Pittsburgh Medical Center
Emily Weisz, PharmD, BCPS, Infectious Disease Clinical Specialist, Lee Health Community Health System
Sandy Estrada, PharmD, Vice President, Medical Affairs, T2 Biosystems, and President Florida Society of, Health-System Pharmacists (FSHP)
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.